^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NC410

    i
    Other names: NC410
    Associations

    News

    Trials
    Company:
    NextCure
    Drug class:
    Cytotoxic T lymphocyte stimulant, Dendritic cell activator, LAIR1 antagonist
    Related drugs:
    Associations

    News

    Trials
    4ms
    NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • NC410
    5ms
    NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression. (PubMed, J Immunol)
    The proportion of collagen-1-positive cells was highest among tumor cells and tumor-infiltrating immune cells versus stromal immune cells, raising the potential role of tumor-associated collagen limiting immune cell infiltration into tumor. Our results support further evaluation of circulating and tumor-associated collagen products and LAIR-1 and LAIR-2 as prognostic biomarkers in advanced OC and as biomarkers for clinical response to NC410 and to other collagen- and LAIR-directed therapies.
    Journal
    |
    LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    |
    NC410
    7ms
    NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P2 trial
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • NC410
    12ms
    KEYNOTE-D88: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=97, Active, not recruiting, NextCure, Inc. | Recruiting --> Active, not recruiting | N=209 --> 97
    Enrollment closed • Enrollment change • Checkpoint inhibition • Metastases
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • NC410
    over1year
    KEYNOTE-D88: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=209, Recruiting, NextCure, Inc. | N=131 --> 209
    Enrollment change • Checkpoint inhibition • Metastases
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • NC410
    almost2years
    A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=131, Recruiting, NextCure, Inc. | Phase classification: P1b/2 --> P1/2
    Phase classification
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • NC410
    almost2years
    Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice. (PubMed, Cancer Immunol Immunother)
    However, combined targeting of LAIR-1 and PD-L1 results in increased tumour control. Thus, additional targeting of the LAIR-1:collagen pathway with NC410 is a promising approach to treating tumours where conventional immunotherapy is ineffective.
    Preclinical • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    |
    LAIR1 expression
    |
    NC410